2Boshier A, Wilton LV, Shakir SA. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999[J]. BJU Ira, 2004, 93(6) :796.
3Milman HA, Arnold SB. Neurologic, psychological, and aggressive disturbances with sildenafll [J]. Ann Pharmacother, 2002,36(7 - 8) : 1 129.
4Jackson G, Gllies H, Osterloh I. Past, present, and future: a 7 - year update of Viagra (sildenafil citrate) [ J]. Int J Clin Pract, 2005, 59(6): 680.
5Vitezic D. A risk - benefit assessment of sildenafil in the treatment of erectile dysfunction [ J ]. Drug Saf, 2001, 24 (4) : 255.
6Cohen JS. Should Patients be Given an Initial Low Test Dose of Sildenafil[J]? Drug Saf, 2000, 23 (1): 1.
7Campbell HE. Clinical monograph for drug formulary review: erectile dysfunction agents[J] . J Manag Care Pharm , 2005, 11(2):151.
8Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors[J]. Int J Clin Pract, 2006, 60(8) : 967.
9Kloner RA. Cardiovascular effects of the 3 phosphodiesterase - 5 inhibitors approved for the treatment of erectile dysfunction[J].Circulation, 2004,110(19) :3149.
10Morales AM, CasiUas M, Turbi C. Patients' preference in the treatment of erectile dysfunction: a critical review of the literature [ J ]. Int J Impot Res,2011,23 (1) :1-8.
